Immune Checkpoint Inhibitor-induced Sicca Syndrome

Samuel Bitoun; Antoine Rousseau; Marjolaine Gosset; Rakiba Belkhir; Thierry Lazure; Xavier Mariette; Gaetane Nocturne

doi:10.1016/j.rdc.2024.02.004

Immune Checkpoint Inhibitor-induced Sicca Syndrome

Rheum Dis Clin North Am. 2024 May;50(2):291-300. doi: 10.1016/j.rdc.2024.02.004.

Authors

Samuel Bitoun¹, Antoine Rousseau², Marjolaine Gosset³, Rakiba Belkhir¹, Thierry Lazure⁴, Xavier Mariette¹, Gaetane Nocturne⁵

Affiliations

¹ Department of Rheumatology, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, 78, Avenue du General Leclerc, Le Kremlin Bicêtre 94270, France.
² Department of Ophthalmology, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicetre, 78 Avenue du General Leclerc, Le Kremlin Bicêtre, 94270, France.
³ Laboratoire Orofacial Pathologies, Imaging and Biotherapies, URP2496, Université de Paris, Montrouge, France; Department of Oral Medicine / Dentistry, AP-HP, Hôpital Charles-Foix, 7 Avenue de La République, Ivry-sur-Seine, 94205, France.
⁴ Department of Pathology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, 78 Rue du Général Leclerc, Le Kremlin Bicêtre, 94270, France.
⁵ Department of Rheumatology, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, 78, Avenue du General Leclerc, Le Kremlin Bicêtre 94270, France. Electronic address: gaetane.nocturne@aphp.fr.

PMID: 38670727
DOI: 10.1016/j.rdc.2024.02.004

Abstract

The development of sicca in patients treated with immune checkpoint inhibitors (ICIs) is undoubtedly an underestimated complication, but one whose functional consequences and impact on quality of life are significant for patients. This update aims to review the frequency of this complication and different clinical pictures. The authors also propose a diagnostic and therapeutic approach to guide clinicians in daily practice.

Keywords: Dryness; Immune checkpoint inhibitors; Immune-related adverse events; Sicca; Sjögren’s disease.

Publication types

Review

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Quality of Life
Sjogren's Syndrome* / chemically induced
Sjogren's Syndrome* / diagnosis
Sjogren's Syndrome* / immunology
Sjogren's Syndrome* / therapy

Substances

Immune Checkpoint Inhibitors